A minimally invasive heart procedure may be a better first-line treatment than medication for people living with advanced ...
Johnson & Johnson (NYSE:JNJ) has entered a definitive agreement to acquire Atraverse Medical, a developer of next-generation ...
Real-world data presented at HRS 2026 add to the body of evidence supporting a shift away from short-duration Holter monitoring toward up to 14 ...
Abbott (NYSE: ABT) today announced new late-breaking data from four trials that demonstrate strong clinical outcomes within its pulsed field ablation (PFA) and conduction system pacing (CSP) ...
First-line treatment with pulsed field ablation (PFA) reduced the risk of recurrence of atrial arrhythmia among patients with persistent atrial fibrillation (Afib), the randomized AVANT GUARD trial ...
Adagio Medical Holdings, Inc. ADGM shares are up during Monday’s premarket session following the announcement of positive ...
Should the transaction complete, J&J will inherit Atraverse’s radiofrequency system for simplifying access to the heart’s left atrium.
Guidelines recommend a trial of antiarrhythmic drugs before catheter ablation for persistent atrial fibrillation. Whether pulsed field ablation (PFA) may be a preferred initial treatment is ...
Rhythm (Nasdaq:IRTC) today announced findings from two real-world analyses supporting its long-term heart monitoring ...
Adagio Medical (Nasdaq:ADGM) today announced new six-month results from its FULCRUM-VT clinical trial evaluating its ablation ...
At the Heart Rhythm Society’s 2026 meeting, Medtronic, Boston Scientific, and Abbott presented encouraging trial data for next‑generation pulsed field ablation (PFA) devices designed to treat ...
LA Chargers coach Jim Harbaugh is having a cardiac ablation during the offseason. It's a procedure to treat an irregular heart rhythm. The procedure involves creating tiny scars in the heart that then ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results